Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 7,300 shares of the firm's stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $53.72, for a total transaction of $392,156.00. Following the completion of the transaction, the executive vice president now directly owns 133,004 shares in the company, valued at $7,144,974.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, June 11th, Fady Ibraham Malik sold 7,788 shares of Cytokinetics stock. The stock was sold at an average price of $53.04, for a total transaction of $413,075.52.
- On Tuesday, May 7th, Fady Ibraham Malik sold 15,547 shares of Cytokinetics stock. The stock was sold at an average price of $65.11, for a total transaction of $1,012,265.17.
- On Tuesday, April 9th, Fady Ibraham Malik sold 32,605 shares of Cytokinetics stock. The stock was sold at an average price of $74.31, for a total transaction of $2,422,877.55.
Cytokinetics Trading Down 1.9 %
The END of Joe Biden
From Banyan Hill Publishing | Ad
One of my political operatives just handed me this story:
“Weeks from now, Joe Biden’s political career will go down in flames…”
Go here now for this breaking news as it happens.
Shares of NASDAQ:CYTK opened at $52.87 on Wednesday. The company has a market capitalization of $5.54 billion, a PE ratio of -9.79 and a beta of 0.75. Cytokinetics, Incorporated has a twelve month low of $25.98 and a twelve month high of $110.25. The firm has a 50 day simple moving average of $57.62 and a 200-day simple moving average of $66.88.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.17). The firm had revenue of $0.84 million for the quarter, compared to analyst estimates of $0.91 million. The company's revenue was down 81.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.38) EPS. As a group, equities research analysts predict that Cytokinetics, Incorporated will post -4.55 EPS for the current fiscal year.
Institutional Trading of Cytokinetics
Several institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. purchased a new stake in Cytokinetics in the 4th quarter valued at $46,308,000. Vanguard Group Inc. raised its position in Cytokinetics by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 10,743,324 shares of the biopharmaceutical company's stock valued at $316,498,000 after purchasing an additional 472,595 shares during the last quarter. HealthInvest Partners AB purchased a new stake in Cytokinetics in the 4th quarter valued at $980,000. Legato Capital Management LLC purchased a new stake in Cytokinetics in the 4th quarter valued at $1,305,000. Finally, Vestal Point Capital LP purchased a new stake in Cytokinetics in the 4th quarter valued at $4,174,000.
Wall Street Analysts Forecast Growth
CYTK has been the subject of several recent analyst reports. Truist Financial cut their price objective on shares of Cytokinetics from $86.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday, May 29th. HC Wainwright restated a "buy" rating and set a $90.00 price objective on shares of Cytokinetics in a research report on Monday, June 17th. B. Riley cut their price objective on shares of Cytokinetics from $122.00 to $92.00 and set a "buy" rating for the company in a research report on Tuesday, June 4th. Needham & Company LLC dropped their price target on shares of Cytokinetics from $108.00 to $72.00 and set a "buy" rating for the company in a research report on Thursday, May 23rd. Finally, Barclays dropped their price objective on shares of Cytokinetics from $100.00 to $95.00 and set an "overweight" rating for the company in a report on Thursday, May 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $77.06.
Read Our Latest Stock Report on CYTK
About Cytokinetics
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
